Search

EHA-SAH Hematology Tutorial on Lymphoid Malignancies and Plasma Cell Dyscrasias

Dates: September 14-15, 2018
Location: Buenos Aires, Argentina
Chairs: D Fantl, R Foà
Co-chair: G Kusminsky

Following successful previous editions, EHA is organizing the second two-day tutorial in close collaboration with the Sociedad Argentina de Hematología (SAH) on “Lymphoid Malignancies and Plasma Cell Dyscrasias”.…

Read more

EHA-PTHiT Hematology Tutorial on Novel Treatment Approaches in Hematologic Malignancies

EHA in collaboration with the Polish Society for Hematology and Transfusion (PTHiT) have decided to postpone this highly anticipated Hematology Tutorial to a future date, to be announced.

Read more

EHA-SWG Scientific Meeting on Mesenchymal Stromal Cells and Tissue Homeostasis

EHA in collaboration with the meeting chairs (W Fibbe & F Dazzi) have decided to postpone this highly anticipated Scientific Meeting to a future date, to be announced.

Read more

EHA-EMN Joint Session at the European Myeloma Network Meeting EMN2023

On Saturday, 22 April, EHA and EMN brought together patients, regulators and clinicians to discuss Novel Endpoints in Multiple Myeloma.

Read more

EHA Statement: Our sustained solidarity with the hematology community in Ukraine

Friday, February 24 marks one year of war. The European Hematology Association (EHA) stands in solidarity with our colleagues and friends in Ukraine.

Read more

ASCERTAIN: EHA joins consortium aiming for better pricing and reimbursement models

November 28, 2022
EHA is a partner in the ASCERTAIN consortium which will develop models for the pricing, cost-benefit assessment, and reimbursement of innovative health technologies in Europe.

Read more

EHA endorses the International COVID-19 Blood Cancer Coalition (ICBCC) Statement

On February 21, the COVID-19 Blood Cancer Coalition (ICBCC), a multi-stakeholder coalition including representatives from the global patient advocacy and clinical community, launched its Joint Patient Impact Statement and Recommendations for protecting immunocompromised blood cancer patients during the COVID-19 pandemic.

Read more